Jan 13, 2021
Orphan Disease Treatment Institute Co., Ltd.：
The results summary of phase 1/2 clinical trial in Japan for DS-5141, which Daiichi Sankyo is jointly developing with the INCJ portfolio company, Orphan Disease Treatment Institute
Daiichi Sankyo Company, Limited today announced the results summary of the Phase 1/2 clinical trial in Japan of DS-5141 in patients with Duchenne muscular dystrophy, which Daiichi Sankyo is jointly developing with the INCJ portfolio company, Orphan Disease Treatment Institute Co., Ltd..
Related Press Releases
- Mar 31, 2023
- INCJ sells its shares in Orphan Disease Treatment Institute Co., Ltd.
- Feb 25, 2016
- INCJ announces additional investment in Orphan Disease Treatment Institute Co., Ltd.